File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience

TitleTreatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience
Authors
KeywordsNasopharyngeal carcinoma
Pattern of failure
Survival
Issue Date2005
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ijrobp
Citation
International Journal of Radiation Oncology - Biology - Physics, 2005, v. 61 n. 4, p. 1107-1116 How to Cite?
AbstractPurpose: To analyze the treatment results achievable for nasopharyngeal carcinoma in the modern era to identify the key failures for future improvement and to provide an updated baseline for future trials. Methods and Results: The results of 2687 consecutive patients treated at all public oncology centers in Hong Kong during 1996-2000 were retrospectively analyzed. The stage distribution (by American Joint Committee on Cancer and International Union Against Cancer staging system, 1997) was 7% Stage I, 41% Stage II, 25% Stage III, and 28% Stage IVA-B. All patients were irradiated with 6-MV photons and the median total dose was 66 Gy. Only 23% of patients had additional treatment with chemotherapy. Results: The 5-year local, nodal, and distant failure-free rates were 85%, 94%, and 81%, respectively; patients with local failure had significantly higher risk of nodal and distant failures. The 5-year progression-free, overall, and cancer-specific survival rates were 63%, 75%, and 80%, respectively. The presenting stage was the most important prognostic factor for all endpoints: with overall survival decreasing from 90% for Stage I to 58% for Stage IVA-B. The results achieved by the 2070 patients treated by radiotherapy alone were almost identical to that of the whole series, the distant failure-free rate among patients with locoregional control was 89% for Stage I-II and 75% for Stage III-IVB. The 860 patients (32%) staged with magnetic resonance imaging achieved significantly better results than those staged by computed tomography, the overall survival being 93% vs. 83% for Stages I-II, and 72% vs. 63% for Stages III-IVB (p = 0.001). Conclusions: Treatment results for nasopharyngeal carcinoma have substantially improved in the modern era; future trials should be based on updated baseline results. Further reduction of distant failure is important for future breakthrough, particularly for patients with advanced disease. © 2005 Elsevier Inc.
Persistent Identifierhttp://hdl.handle.net/10722/71918
ISSN
2015 Impact Factor: 4.495
2015 SCImago Journal Rankings: 2.274
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLee, AWMen_HK
dc.contributor.authorSze, WMen_HK
dc.contributor.authorAu, JSKen_HK
dc.contributor.authorLeung, SFen_HK
dc.contributor.authorLeung, TWen_HK
dc.contributor.authorChua, DTTen_HK
dc.contributor.authorZee, BCYen_HK
dc.contributor.authorLaw, SCKen_HK
dc.contributor.authorTeo, PMLen_HK
dc.contributor.authorTung, SYen_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorLau, WHen_HK
dc.date.accessioned2010-09-06T06:36:29Z-
dc.date.available2010-09-06T06:36:29Z-
dc.date.issued2005en_HK
dc.identifier.citationInternational Journal of Radiation Oncology - Biology - Physics, 2005, v. 61 n. 4, p. 1107-1116en_HK
dc.identifier.issn0360-3016en_HK
dc.identifier.urihttp://hdl.handle.net/10722/71918-
dc.description.abstractPurpose: To analyze the treatment results achievable for nasopharyngeal carcinoma in the modern era to identify the key failures for future improvement and to provide an updated baseline for future trials. Methods and Results: The results of 2687 consecutive patients treated at all public oncology centers in Hong Kong during 1996-2000 were retrospectively analyzed. The stage distribution (by American Joint Committee on Cancer and International Union Against Cancer staging system, 1997) was 7% Stage I, 41% Stage II, 25% Stage III, and 28% Stage IVA-B. All patients were irradiated with 6-MV photons and the median total dose was 66 Gy. Only 23% of patients had additional treatment with chemotherapy. Results: The 5-year local, nodal, and distant failure-free rates were 85%, 94%, and 81%, respectively; patients with local failure had significantly higher risk of nodal and distant failures. The 5-year progression-free, overall, and cancer-specific survival rates were 63%, 75%, and 80%, respectively. The presenting stage was the most important prognostic factor for all endpoints: with overall survival decreasing from 90% for Stage I to 58% for Stage IVA-B. The results achieved by the 2070 patients treated by radiotherapy alone were almost identical to that of the whole series, the distant failure-free rate among patients with locoregional control was 89% for Stage I-II and 75% for Stage III-IVB. The 860 patients (32%) staged with magnetic resonance imaging achieved significantly better results than those staged by computed tomography, the overall survival being 93% vs. 83% for Stages I-II, and 72% vs. 63% for Stages III-IVB (p = 0.001). Conclusions: Treatment results for nasopharyngeal carcinoma have substantially improved in the modern era; future trials should be based on updated baseline results. Further reduction of distant failure is important for future breakthrough, particularly for patients with advanced disease. © 2005 Elsevier Inc.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ijrobpen_HK
dc.relation.ispartofInternational Journal of Radiation Oncology - Biology - Physicsen_HK
dc.rightsInternational Journal of Radiation: Oncology - Biology - Physics. Copyright © Elsevier Inc.en_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectPattern of failureen_HK
dc.subjectSurvivalen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshDisease-Free Survivalen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHong Kongen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNasopharyngeal Neoplasms - drug therapy - mortality - radiotherapyen_HK
dc.subject.meshRadiotherapy Dosageen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshSurvival Rateen_HK
dc.subject.meshTreatment Failureen_HK
dc.titleTreatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experienceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0360-3016&volume=61&spage=1107&epage=16&date=2005&atitle=Treatment+results+for+nasopharyngeal+carcinoma+in+the+modern+era:+the+Hong+Kong+experienceen_HK
dc.identifier.emailChua, DTT: dttchua@hkucc.hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.authorityChua, DTT=rp00415en_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ijrobp.2004.07.702en_HK
dc.identifier.pmid15752890-
dc.identifier.scopuseid_2-s2.0-20044378115en_HK
dc.identifier.hkuros101401en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-20044378115&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume61en_HK
dc.identifier.issue4en_HK
dc.identifier.spage1107en_HK
dc.identifier.epage1116en_HK
dc.identifier.isiWOS:000227604200017-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLee, AWM=17035384900en_HK
dc.identifier.scopusauthoridSze, WM=7003795941en_HK
dc.identifier.scopusauthoridAu, JSK=7101921203en_HK
dc.identifier.scopusauthoridLeung, SF=7202044876en_HK
dc.identifier.scopusauthoridLeung, TW=7202110934en_HK
dc.identifier.scopusauthoridChua, DTT=7006773480en_HK
dc.identifier.scopusauthoridZee, BCY=7006378172en_HK
dc.identifier.scopusauthoridLaw, SCK=7202241299en_HK
dc.identifier.scopusauthoridTeo, PML=7006685066en_HK
dc.identifier.scopusauthoridTung, SY=7102858954en_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridLau, WH=7402933278en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats